Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MVD | P53602 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26665546 | 0.80 | ALDH1A1 (0.42) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL8648874 | 0.78 | CA12 (0.44) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL12521172 | 0.78 | EGLN1 (0.40) | EGLN1ALDH1A1TSHRMVDLMNA | |
| SCHEMBL4496911 | 0.76 | CA12 (0.43) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL2114681 | 0.75 | ALDH1A1 (0.46) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL1330762 | 0.75 | ALDH1A1 (0.46) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL1331806 | 0.75 | ALDH1A1 (0.46) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL51874 | 0.73 | CYP2C9 (0.37) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL15780800 | 0.73 | CYP2C9 (0.41) | EGLN1CA12CA1CA2CA9 | |
| SCHEMBL15821786 | 0.72 | CYP2C9 (0.36) | EGLN1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619086-B2 | HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080139579-A1 | Hiv Integrase Inhibitors | MERCK & CO., INC. (US) | 2008-06-12 | — | — | US | disclosed |
| EP-1725535-A2 | HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005086700-A2 | HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139579-A1 | Hiv Integrase Inhibitors | INTS9, CDK9, PRDM9 | EGLN1 3773/4885CA12 4863/4885CA1 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.